Product Description
Plinabulin is an investigational small molecule that is in the new class of selective immunomodulating microtubule-binding agent. It features a unique mechanism of action (MOA) compared to current standard-of-care chemotherapeutics and conventional microtubule-binding agents, which results in differentiated safety and efficacy profile. Plinabulin binds in a differentiated pocket of tubulin with different binding kinetics from other tubulin binding agents, including taxane, vinca, and colchicine (La Sala Chem 2019). This differentiation in binding not only results in well tolerated safety profile in >700 cancer patients, but also in differentiated immune-modulating biological activities for plinabulin. (Sourced from: https://beyondspringpharma.com/pipeline/plinabulin/)
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: Breakthrough Therapy - Neutropenia *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BeyondSpring
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Ukraine, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Neutropenia
Phase 2: Multiple Myeloma|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AHCT | P2 |
Active, not recruiting |
Multiple Myeloma |
2025-11-01 |
|
| KeyPemls-004 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2024-12-31 |
|
| BTCRC-LUN17-127 | P2 |
Completed |
Small Cell Lung Cancer |
2023-09-25 |
|
| NCT02812667 | P1 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2022-07-04 |